Placebo + Tadalafil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
Feb 1, 2009 → Jun 1, 2009
NCT ID
NCT00833638About Placebo + Tadalafil
Placebo + Tadalafil is a approved stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00833638. Target conditions include Erectile Dysfunction.
What happened to similar drugs?
11 of 20 similar drugs in Erectile Dysfunction were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00833638 | Approved | Completed |
| NCT00827242 | Phase 3 | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo | Yuhan | Phase 2 | 35 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 43 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 32 |
| LY2452473 + Tadalafil + LY900010 | Eli Lilly | Phase 1 | 29 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| tadalafil | Eli Lilly | Phase 3 | 40 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 35 |
| Tadalafil | Eli Lilly | Approved | 43 |
| tadalafil + placebo | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil Citrate | Eli Lilly | Approved | 43 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 40 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| tadalafil | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 43 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 40 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 40 |
| dapoxetine | Johnson & Johnson | Phase 3 | 40 |
| Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor) | Johnson & Johnson | Phase 3 | 40 |